News
-
-
REGULATED PRESS RELEASE
bioMérieux – 2023 Financial Results
-
-
REGULATED PRESS RELEASE
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux, a world leader in in vitro diagnostics, announces the appointment of two new Executive Committee members, Dr. Charles K. Cooper and Céline Roger-Dalbert, to lead Medical Affairs and Research & Development, respectively. Dr. Cooper brings extensive medical and leadership background from Siemens Healthcare Diagnostics and U.S. Food & Drug Administration, while Céline Roger-Dalbert boasts over 25 years of in vitro diagnostic experience, with significant contributions to new product launches and over 20 patent applications. Their nominations signify bioMérieux's commitment to addressing global patients' needs and driving innovation, aligning with the company's strategy. For more information, visit www.biomerieux.com. -
REGULATED PRESS RELEASE
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux has acquired LUMED, a software company specializing in clinical decision support systems to optimize antimicrobial prescriptions and monitor healthcare-associated infections. This acquisition reinforces bioMérieux's commitment to combat antimicrobial resistance and improve infection prevention and control through advanced software solutions. -
REGULATED PRESS RELEASE
bioMérieux – Third-Quarter 2023 Business Review
-
REGULATED PRESS RELEASE
bioMérieux makes strategic investment in Oxford Nanopore
-
